New York to probe Mylan EpiPen contracts for schools
- Wall Street dips as Verizon drags; AmEx curbs losses
- AT&T (T) Said to Discuss Idea of Takeover in Time Warner (TWX) Meetings
- UPDATE: Qualcomm (QCOM), NXP Semiconductors (NXPI) Deal Could be Announced Next Week - Bloomberg
- Tesla (TSLA) Announces Self-Driving Hardware for All Vehicles in Production; Includes Model 3
- Walgreens Boots Alliance (WBA) Tops Q4 EPS by 8c; Guides FY17 EPS
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
WASHINGTON (Reuters) - New York has opened a probe into whether Mylan Pharmaceuticals (NASDAQ: MYL) broke antitrust law in writing contracts to provide EpiPens to some schools systems, state Attorney General Eric Schneiderman said in a statement on Tuesday.
A person briefed on the matter said the New York attorney general's office has subpoenaed documents from Mylan over the EpiPen program.
There had been allegations that schools which had used Mylan's EpiPen4Schools program, which gives many schools the devices for free, were contractually barred from buying products from Mylan competitors for a year. Senators Richard Blumenthal and Amy Klobuchar asked the Federal Trade Commission on Tuesday to investigate the allegation.
Mylan did not immediately respond to a request for comment.
(Reporting by Diane Bartz and David Shepardson; Editing by David Gregorio)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Mylan (MYL), Theravance Biopharma(TBPH) Announce Positive Data from Two Revefenacin Phase 3s as COPD Treatment
- U.S. start-up R3, banks test Ripple's cross-border payments technology
Create E-mail Alert Related CategoriesGeneral News, Litigation, Reuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!